M3 : to Merge Subsidiaries Mediscience Planning and MIC Medical ~ Acceleration in Optimizing Digitalized Clinical Trials ~
February 18, 2021 at 01:09 am EST
Share
FOR IMMEDIATE RELEASE: 2021/2/18
M3, Inc.
M3 to Merge Subsidiaries Mediscience Planning and MIC Medical ~ Acceleration in Optimizing Digitalized Clinical Trials ~
M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL:https://corporate.m3.com/; "M3," below) has announced the merger of its subsidiaries, Mediscience Planning, Inc. ("MPI," below) and MIC Medical Corporate ("MIC," below) as of June 1, 2021 (planned). This merger will further streamline the digitalized clinical trials business.
M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 290,000+ members, equivalent to over 90% of physicians in Japan, and offers services such as the "MR-kun" family services, marketing research capabilities paneling the physician members.
The Evidence Solution business includes clinical trial related services centered around "Mr. Finder" which excavates institutions and patient participants for clinical studies, and increasing efficiency of clinical trials supported by Contract Research Organizations (CRO) and Site Management Organizations (SMO) provided through various group companies. MPI and MIC are CROs of M3 Group, both of which offer clinical trial support services.
Through this merger, MPI will absorb MIC to become a CRO managing over 800 CRAs to run clinical studies. Akinori Urae, currently the Representative Director of MPI, is appointed to become CEO of MPI after this merger.
M3 Group has been streamlining its organizational structure of clinical trial related services, such as its integration of SMOs within the group. This merger will accelerate the productivity of clinical trial services through leveraging the integration of the internet, IT, and m3.com.
Expected Synergies
1. Service quality improvement and one-stop service provision that leverage strengths of both companies
2. Resource optimization and improvement of sales structures
3. Accumulation of solutions such as "Mr. Finder" that leverage m3.com
4. Employee productivity and margin improvement via investment in IT infrastructure and management cost reduction
1
Attachments
Original document
Permalink
Disclaimer
M3 Inc. published this content on 18 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 February 2021 06:08:06 UTC.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.
M3, INC. 
